These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 18281765)

  • 21. Capecitabine in the treatment of metastatic renal cell carcinoma failing immunotherapy.
    Wenzel C; Locker GJ; Schmidinger M; Mader R; Kramer G; Marberger M; Rauchenwald M; Zielinski CC; Steger GG
    Am J Kidney Dis; 2002 Jan; 39(1):48-54. PubMed ID: 11774101
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Effect of second-line treatment with capecitabine and thalidomide in patients with advanced pancreatic cancer].
    Shi SB; Ma TH; Tang XY; Li CH
    Zhonghua Zhong Liu Za Zhi; 2013 Apr; 35(4):301-4. PubMed ID: 23985261
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase II trial of weekly intravenous gemcitabine and cisplatin with continuous infusion fluorouracil in patients with metastatic renal cell carcinoma.
    George CM; Vogelzang NJ; Rini BI; Geoffroy FJ; Kollipara P; Stadler WM
    Ann Oncol; 2002 Jan; 13(1):116-20. PubMed ID: 11863091
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase II trial of gemcitabine, capecitabine, and bevacizumab in metastatic renal carcinoma.
    Chung EK; Posadas EM; Kasza K; Karrison T; Manchen E; Hahn OM; Stadler WM
    Am J Clin Oncol; 2011 Apr; 34(2):150-4. PubMed ID: 20395787
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: a phase I/II trial.
    Hess V; Salzberg M; Borner M; Morant R; Roth AD; Ludwig C; Herrmann R
    J Clin Oncol; 2003 Jan; 21(1):66-8. PubMed ID: 12506172
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase II trial of fixed-dose rate gemcitabine plus capecitabine in metastatic/advanced biliary tract cancer patients.
    Santini D; Virzi V; Vasile E; Vincenzi B; Catalano V; Graziano F; Masi G; Bronte G; Russo A; Falcone A; Tonini G
    Oncology; 2012; 82(2):75-82. PubMed ID: 22327844
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Capecitabine monotherapy and in combination with immunotherapy in the treatment of metastatic renal cell carcinoma.
    Wenzel C; Locker GJ; Bartsch R; Pluschnig U; Mader R; Hussian D; Kramer G; Marberger M; Lintner C; Rauchenwald M; Zielinski CC; Steger GG
    Anticancer Drugs; 2003 Nov; 14(10):779-84. PubMed ID: 14597871
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Docetaxel second-line therapy in patients with advanced pancreatic cancer: a retrospective study.
    Saif MW; Syrigos K; Penney R; Kaley K
    Anticancer Res; 2010 Jul; 30(7):2905-9. PubMed ID: 20683031
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer.
    Starling N; Watkins D; Cunningham D; Thomas J; Webb J; Brown G; Thomas K; Oates J; Chau I
    J Clin Oncol; 2009 Nov; 27(33):5499-505. PubMed ID: 19858399
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Phase I-II dose escalation study of fixed-dose rate gemcitabine, oxaliplatin and capecitabine every two weeks in advanced cholangiocarcinomas.
    Lassen U; Jensen LH; Sorensen M; Rohrberg KS; Ujmajuridze Z; Jakobsen A
    Acta Oncol; 2011 Apr; 50(3):448-54. PubMed ID: 20670085
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981.
    Tagawa ST; Milowsky MI; Jeske S; Mazumdar M; Kung S; Sung M; Lehrer D; Matulich D; Selzer J; Wright JJ; Nanus DM
    Am J Clin Oncol; 2011 Oct; 34(5):443-8. PubMed ID: 20881475
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas.
    Ko AH; Espinoza AM; Jones KA; Venook AP; Bergsland EK; Kelley RK; Dito E; Ong A; Hanover CS; Coakley FV; Tempero MA
    Am J Clin Oncol; 2012 Oct; 35(5):411-7. PubMed ID: 21552099
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Retrospective study on regimens of capecitabine-based chemotherapy in the treatment for advanced gastric cancer].
    Zhang J; Xiao Y; Lu M; Li J; Zhang XD; Li Y; Shen L
    Zhonghua Zhong Liu Za Zhi; 2009 Apr; 31(4):312-5. PubMed ID: 19615292
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I trial of capecitabine plus everolimus (RAD001) in patients with previously treated metastatic gastric cancer.
    Lim T; Lee J; Lee DJ; Lee HY; Han B; Baek KK; Ahn HK; Lee SJ; Park SH; Park JO; Park YS; Lim HY; Kim KM; Kang WK
    Cancer Chemother Pharmacol; 2011 Jul; 68(1):255-62. PubMed ID: 21526353
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gemcitabine and capecitabine in previously anthracycline-treated metastatic breast cancer: a multicenter phase II study (SOLTI 0301 trial).
    Ciruelos EM; Cortés J; Cortés-Funes H; Mayordomo JI; Bermejo B; Ojeda B; García E; Rodríguez CA; Muñoz M; Gómez P; Manso L; Andrés R; Lluch A; Saura C; Mendiola C; Baselga J
    Ann Oncol; 2010 Jul; 21(7):1442-1447. PubMed ID: 19940004
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase I clinical trial of low-dose interferon-alpha-2A, thalidomide plus gemcitabine and capecitabine for patients with progressive metastatic renal cell carcinoma.
    Amato RJ; Khan M
    Cancer Chemother Pharmacol; 2008 May; 61(6):1069-73. PubMed ID: 17701037
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis.
    Fine RL; Fogelman DR; Schreibman SM; Desai M; Sherman W; Strauss J; Guba S; Andrade R; Chabot J
    Cancer Chemother Pharmacol; 2008 Jan; 61(1):167-75. PubMed ID: 17440727
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the 'Arbeitsgemeinschaft Internistische Onkologie'.
    Boeck S; Vehling-Kaiser U; Waldschmidt D; Kettner E; Märten A; Winkelmann C; Klein S; Kojouharoff G; Gauler T; Fischer von Weikersthal L; Clemens MR; Geissler M; Greten TF; Hegewisch-Becker S; Neugebauer S; Heinemann V
    Anticancer Drugs; 2010 Jan; 21(1):94-100. PubMed ID: 19770635
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Gemcitabine combined with capecitabine in the treatment for 41 patients with relapsed or metastatic biliary tract carcinoma].
    Yu ZY; Ouyang XN; Chen ZS; Li J; Chen X; Xie FW
    Zhonghua Zhong Liu Za Zhi; 2008 Feb; 30(2):144-6. PubMed ID: 18646701
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Phase II study of capecitabine combined with gemcitabine in patients with advanced gallbladder carcinoma.
    Cho JY; Nam JS; Park MS; Yu JS; Paik YH; Lee SJ; Lee DK; Yoon DS
    Yonsei Med J; 2005 Aug; 46(4):526-31. PubMed ID: 16127778
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.